Companies › Kexing Biopharm
4 active drug programs in 12 registered trials: 8 Phase 3, 2 Phase 1, 2 Phase 2; Oncology, Metabolic and endocrine, Infectious disease, Hematology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Human interferon α1b Inhalation Solution Interferon alpha-1b, antiviral cytokine | IFNA1 | Phase 3 | Respiratory Syncytial Virus Infections | Jun 2027 |
| GB06 Recombinant human growth hormone (biosimilar) | GH1 | Phase 3 | Growth Hormone Deficiency (GHD) | Jul 2028 |
| Pegfilgrastim Granulocyte colony stimulating factor receptor agonist | CSF3R | Phase 3 | Neutropenia, Chemotherapy-Induced Febrile; Non-Hodgkin's Lymphoma; Multiple Myeloma; Esophageal Cancer … | – |
| GB18 GDF15 monoclonal antibody antagonist | GDF15 | Phase 1 | Cachexia; Cancer; Cancer Cachexia (CC) | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07237464 | GB18 | Phase 1 | Cancer Cachexia (CC) | Oncology | Jan 2026 |
| NCT06711523 | Pegfilgrastim | Phase 3 | Neutropenia, Chemotherapy-Induced Febrile | Oncology | Jun 2026 |
| NCT06520163 | Pegfilgrastim | Phase 3 | Non-Hodgkin's Lymphoma | Oncology | Aug 2026 |
| NCT06520176 | Pegfilgrastim | Phase 3 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT03571633 | Pegfilgrastim | Phase 2 | HER2-positive Breast Cancer | Oncology | Jan 2027 |
| NCT06363370 | Human interferon α1b Inhalation Solution | Phase 3 | Respiratory Syncytial Virus Infections | Infectious disease | Jun 2027 |
| NCT07519564 | GB18 | Phase 1 | Cachexia; Cancer | Oncology | Sep 2027 |
| NCT03731442 | Pegfilgrastim | Phase 3 | Esophageal Cancer | Oncology | Oct 2027 |
| NCT00433420 | Pegfilgrastim | Phase 3 | Breast Cancer | Oncology | Dec 2027 |
| NCT07553351 | GB06 | Phase 3 | Growth Hormone Deficiency (GHD) | Metabolic and endocrine | Jul 2028 |
| NCT01624805 | Pegfilgrastim | Phase 2 | Aplastic Anemia | Hematology | Jun 2029 |
| NCT02375204 | Pegfilgrastim | Phase 3 | Germ Cell Tumor | Oncology | Jun 2031 |
Guangzhou Gloria Biosciences Xynomic Pharmaceuticals Dizal Pharmaceuticals Evopoint Biosciences Tolmar
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.